Zoetis Inc. (ZTS)

Market Cap	55.07B
Revenue (ttm)	9.40B +2.7%
Net Income	2.65B +9.1%
EPS	5.94 +11.6%
Shares Out	440.69M
PE Ratio	21.05
Forward PE	18.87
Dividend	$2.12 (1.70%)
Ex-Dividend Date	Jan 20, 2026

Volume	3,587,676
Open	123.54
Previous Close	123.92
Day's Range	123.05 - 126.29
52-Week Range	115.25 - 177.40
Beta	0.97
Analysts	Buy
Price Target	166.60 (+33.32%)
Earnings Date	Feb 12, 2026

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 13,800
• Stock Exchange: NYSE
• Ticker Symbol: ZTS
• Website: https://www.zoetis.com

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Analyst Summary

According to 11 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $166.6, which is an increase of 33.32% from the latest price.

Price Target

$166.6

(33.32% upside)

Analyst Consensus: Buy